Unstable angina non ST elevation myocardial infarction beta blockers: Difference between revisions
Jump to navigation
Jump to search
(New page: {{SI}} {{WikiDoc Cardiology Network Infobox}} {{CMG}} '''Associate Editor-In-Chief:''' Smita Kohli, M.D.; Lakshmi Gopalakrishnan, M.B.B.S.; Varun Kumar, M.B.B.S. {{Editor Join}} ...) |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{{ | '''{{Infobox_Disease | ||
{{ | | Name = Unstable angina pectoris | ||
| Image = | |||
| Caption = | |||
| DiseasesDB = 8695 | |||
| ICD10 = {{ICD10|I|20||i|20}} | |||
| ICD9 = {{ICD9|413}} | |||
| ICDO = | |||
| OMIM = | |||
| MedlinePlus = | |||
| eMedicineSubj = med | |||
| eMedicineTopic = 133 | |||
| MeshID = D000787 | |||
}} | |||
{{Search infobox}} | |||
{{CMG}} | {{CMG}} | ||
__NOTOC__ | |||
'''Associate Editor-In-Chief:''' {{CZ}}; Smita Kohli, M.D.; {{NMG}}; [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. | |||
{{Editor Join}} | |||
==Mechanism of Benefit:== | |||
*In [[Unstable angina]]/[[NSTEMI]], the primary benefits of [[beta blockers]] are due to inhibition of beta-1 adrenergic receptors, which results in a decrease in cardiac work and myocardial oxygen demand. | |||
*Slowing of the [[heart rate]] also has a favorable effect, acting not only to reduce myocardial oxygen demand(MVO2) but also to increase the duration of [[diastole]] and diastolic pressure-time, a determinant of forward coronary flow and collateral flow<ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=[[Journal of the American College of Cardiology]] |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi=10.1016/j.jacc.2007.02.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)00511-6 |accessdate=2011-04-11}}</ref>. | |||
==Indications:== | |||
*In the absence of contraindication(especially [[hypotension]], [[heart failure]] and hemodyanamic instability), [[beta blockers]] should be initiated either orally or intravenously within first 24 h. | |||
==Contra-indication:== | |||
*Patients with marked first-degree [[AV block]] (i.e., ECG PR interval greater than 0.24 s), any form of second- or third-degree AV block in the absence of a functioning implanted [[pacemaker]], a history of [[asthma]], severe [[LV dysfunction]] or [[HF]] (e.g., rales or S3 gallop) or at high risk for [[shock]] (see below) '''should not receive [[beta blockers]] on an acute basis'''. | |||
==Clinical Trial data:== | |||
Two recent studies(GUSTO-I and COMMIT) have revealed that early aggressive beta blockade poses a substantial net hazard in ''hemodynamically unstable patients'' and should be avoided. | |||
== | In the COMMIT study<ref name="pmid16271643">{{cite journal |author=Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS |title=Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial |journal=[[Lancet]] |volume=366 |issue=9497 |pages=1622–32 |year=2005 |month=November |pmid=16271643 |doi=10.1016/S0140-6736(05)67661-1 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)67661-1 |accessdate=2011-04-11}}</ref>, the utility of early intravenous followed by oral [[beta blocker]] (metoprolol) was tested in 45,852 patients with MI (93% had [[STEMI]], 7% had [[NSTEMI]]) which showed that neither the composite of death, [[re]]infarction, or [[cardiac arrest]] nor death alone was reduced for up to 28 d in the hospital. Overall, a modest reduction in [[re]]infarction and [[ventricular fibrillation]] (which was seen after day 1) was counterbalanced by an increase in [[cardiogenic shock]], which occurred early (first day) and primarily in those who were hemodynamically compromised or in [[HF]] or who were stable but at high risk of development of [[shock]]. | ||
'''Risk factors for shock''' were older age, female sex, time delay, higher [[Killip class]], lower blood pressure, previous [[hypertension]], higher [[heart rate]], and [[ECG]] abnormality. | |||
In GUSTO-I retrospective analyses<ref name="pmid9741504">{{cite journal |author=Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, van de Werf F, Stebbins AL, Lee KL, Topol EJ, Armstrong PW |title=Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries |journal=[[Journal of the American College of Cardiology]] |volume=32 |issue=3 |pages=634–40 |year=1998 |month=September |pmid=9741504 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0735109798002794 |accessdate=2011-04-11}}</ref>, the administration of intravenous [[atenolol]] combined with late oral administration was associated with higher mortality than late oral administration alone. The authors concluded that late oral administration of atenolol might be sufficient and may offer just as good of outcomes as that coupled with early IV administration. Overall, the rationale for [[beta-blocker]] use in all forms of [[CAD]], including [[Unstable angina]], is generally favorable, with the exception of initial [[heart failure]]. | |||
==ACC / AHA Guidelines (DO NOT EDIT) <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, ''et al'' |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=JACC |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi:10.1016/j.jacc.2007.02.013 |url=}}</ref><ref name="pmid21444888">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS |title=2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |journal=[[Circulation]] |volume= |issue= |pages= |year=2011 |month=March |pmid=21444888 |doi=10.1161/CIR.0b013e318212bb8b |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=21444888 |accessdate=2011-04-08}}</ref>== | ==ACC / AHA Guidelines (DO NOT EDIT) <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, ''et al'' |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=JACC |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi:10.1016/j.jacc.2007.02.013 |url=}}</ref><ref name="pmid21444888">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS |title=2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |journal=[[Circulation]] |volume= |issue= |pages= |year=2011 |month=March |pmid=21444888 |doi=10.1161/CIR.0b013e318212bb8b |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=21444888 |accessdate=2011-04-08}}</ref>== | ||
{{cquote| | {{cquote| | ||
===Class I=== | |||
1.Oral [[beta blocker]] therapy should be initiated within the first 24 h for patients who do not have 1 or more of the following: a- Signs of [[HF]], b- Evidence of a [[low output state]], c- Increased risk for [[cardiogenic shock]], or d- Other relative contraindications to beta blockade (PR interval >0.24 sec, second or third degree [[heart block]], active [[asthma]], or reactive airway disease). (Level of Evidence: B) | |||
===Class IIa=== | ===Class IIa=== | ||
1. It is reasonable to administer intravenous (IV) [[beta blockers]] at the time of presentation for [[hypertension]] to [[Unstable angina]] / [[NSTEMI]] patients who do not have 1 or more of the following: a- Signs of [[HF]], b- Evidence of a [[low output state]], c- Increased risk for [[cardiogenic shock]], d- Other relative contraindications to beta blockade (PR interval >0.24 s, second or third degree [[heart block]], active [[asthma]], or reactive airway disease). (Level of Evidence: B) | |||
===Class III=== | ===Class III=== | ||
1. It may be harmful to administer intravenous [[beta blockers]] to [[Unstable angina]] / [[NSTEMI]] patients who have contraindications to beta blockade, signs of [[HF]] or [[low output state]], or other risk factors for [[cardiogenic shock]]. (Level of Evidence: A)}} | |||
==Sources== | |||
*2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines<ref name="pmid21444888">{{cite journal |author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS |title=2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |journal=[[Circulation]] |volume= |issue= |pages= |year=2011 |month=March |pmid=21444888 |doi=10.1161/CIR.0b013e318212bb8b |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=21444888 |accessdate=2011-04-08}}</ref> | |||
* The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction <ref name="pmid17692738">{{cite journal |author=Anderson JL, Adams CD, Antman EM, ''et al'' |title=ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine |journal=JACC |volume=50 |issue=7 |pages=e1–e157 |year=2007 |month=August |pmid=17692738 |doi:10.1016/j.jacc.2007.02.013 |url=}}</ref> | |||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
[[Category: Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Emergency medicine]] | |||
{{ | {{SIB}} | ||
{{ | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | |||
Revision as of 15:31, 11 April 2011
| Unstable angina pectoris | |
| ICD-10 | I20 |
|---|---|
| ICD-9 | 413 |
| DiseasesDB | 8695 |
| eMedicine | med/133 |
| MeSH | D000787 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Smita Kohli, M.D.; Neil Gheewala, M.D. [3]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Mechanism of Benefit:
- In Unstable angina/NSTEMI, the primary benefits of beta blockers are due to inhibition of beta-1 adrenergic receptors, which results in a decrease in cardiac work and myocardial oxygen demand.
- Slowing of the heart rate also has a favorable effect, acting not only to reduce myocardial oxygen demand(MVO2) but also to increase the duration of diastole and diastolic pressure-time, a determinant of forward coronary flow and collateral flow[1].
Indications:
- In the absence of contraindication(especially hypotension, heart failure and hemodyanamic instability), beta blockers should be initiated either orally or intravenously within first 24 h.
Contra-indication:
- Patients with marked first-degree AV block (i.e., ECG PR interval greater than 0.24 s), any form of second- or third-degree AV block in the absence of a functioning implanted pacemaker, a history of asthma, severe LV dysfunction or HF (e.g., rales or S3 gallop) or at high risk for shock (see below) should not receive beta blockers on an acute basis.
Clinical Trial data:
Two recent studies(GUSTO-I and COMMIT) have revealed that early aggressive beta blockade poses a substantial net hazard in hemodynamically unstable patients and should be avoided.
In the COMMIT study[2], the utility of early intravenous followed by oral beta blocker (metoprolol) was tested in 45,852 patients with MI (93% had STEMI, 7% had NSTEMI) which showed that neither the composite of death, reinfarction, or cardiac arrest nor death alone was reduced for up to 28 d in the hospital. Overall, a modest reduction in reinfarction and ventricular fibrillation (which was seen after day 1) was counterbalanced by an increase in cardiogenic shock, which occurred early (first day) and primarily in those who were hemodynamically compromised or in HF or who were stable but at high risk of development of shock. Risk factors for shock were older age, female sex, time delay, higher Killip class, lower blood pressure, previous hypertension, higher heart rate, and ECG abnormality.
In GUSTO-I retrospective analyses[3], the administration of intravenous atenolol combined with late oral administration was associated with higher mortality than late oral administration alone. The authors concluded that late oral administration of atenolol might be sufficient and may offer just as good of outcomes as that coupled with early IV administration. Overall, the rationale for beta-blocker use in all forms of CAD, including Unstable angina, is generally favorable, with the exception of initial heart failure.
ACC / AHA Guidelines (DO NOT EDIT) [1][4]
| “ |
Class I1.Oral beta blocker therapy should be initiated within the first 24 h for patients who do not have 1 or more of the following: a- Signs of HF, b- Evidence of a low output state, c- Increased risk for cardiogenic shock, or d- Other relative contraindications to beta blockade (PR interval >0.24 sec, second or third degree heart block, active asthma, or reactive airway disease). (Level of Evidence: B) Class IIa1. It is reasonable to administer intravenous (IV) beta blockers at the time of presentation for hypertension to Unstable angina / NSTEMI patients who do not have 1 or more of the following: a- Signs of HF, b- Evidence of a low output state, c- Increased risk for cardiogenic shock, d- Other relative contraindications to beta blockade (PR interval >0.24 s, second or third degree heart block, active asthma, or reactive airway disease). (Level of Evidence: B) Class III1. It may be harmful to administer intravenous beta blockers to Unstable angina / NSTEMI patients who have contraindications to beta blockade, signs of HF or low output state, or other risk factors for cardiogenic shock. (Level of Evidence: A) |
” |
Sources
- 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[4]
- The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [1]
References
- ↑ 1.0 1.1 1.2 Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". Journal of the American College of Cardiology. 50 (7): e1–e157. doi:10.1016/j.jacc.2007.02.013. PMID 17692738. Retrieved 2011-04-11. Unknown parameter
|month=ignored (help) - ↑ Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS (2005). "Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial". Lancet. 366 (9497): 1622–32. doi:10.1016/S0140-6736(05)67661-1. PMID 16271643. Retrieved 2011-04-11. Unknown parameter
|month=ignored (help) - ↑ Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, van de Werf F, Stebbins AL, Lee KL, Topol EJ, Armstrong PW (1998). "Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries". Journal of the American College of Cardiology. 32 (3): 634–40. PMID 9741504. Retrieved 2011-04-11. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS (2011). "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e318212bb8b. PMID 21444888. Retrieved 2011-04-08. Unknown parameter
|month=ignored (help)